The Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, will transition from CEO to Non-Executive Director and Chairman of the Board of Directors; and Karen Massey, currently Chief Operating Officer, will assume the role of CEO and Executive Director, pending shareholder approval.
DiogenX SA